Scholarlink

<p>A diarrheal disease related to <i>Shigella</i> is a major public health challenge in the world, highlighting the requirement of efficient vaccines. This study investigated the immunogenicity of a chimeric protein containing IpaB, StxB, IpaD and VirG (BSDV) that was encapsulated in chitosan nanoparticles as a vaccine candidate. The BSDV protein was expressed, purified, and loaded into chitosan nanoparticles using the ionic gelation method. Nanoparticle size, zeta potential, and protein release were characterized. Mice were immunized with free BSDV, BSDV with adjuvant, or BSDV encapsulated in chitosan nanoparticles, and immune responses (IgG and IgA) as well as survival after <i>Shigella dysenteriae</i> and Shiga toxin (Stx) challenge were evaluated. The purified BSDV protein had a final concentration of 16&#xa0;mg/L. The chitosan nanoparticles showed an average size of 234.2 ± 23.9&#xa0;nm with a zeta potential of 15.1 ± 0.9&#xa0;mV. Protein release was gradual, with 50% released within 24&#xa0;h and 72% by day 8. Immunization with BSDV encapsulated in chitosan nanoparticles induced significantly higher IgG and IgA titers compared to the other groups (p &lt; 0.05) and provided 100% protection against 10LD<sub>50</sub> of <i>S. dysenteriae</i> and 80% against 100LD<sub>50</sub> of Stx. Our results indicate that chitosan-encapsulated BSDV induced protective immunity and is a promising candidate vaccine against the infections of <i>Shigella dysenteriae</i>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A chitosan-encapsulated chimeric protein protects against adherence and toxicity of Shigella dysenteriae

  • 期刊论文

  • 发表日期：

    2026年1月28日

查看全文
  • Mojtaba Zafarmand-Samarin,
  • Alireza Felegary,
  • Shahram Nazarian

摘要

A diarrheal disease related to Shigella is a major public health challenge in the world, highlighting the requirement of efficient vaccines. This study investigated the immunogenicity of a chimeric protein containing IpaB, StxB, IpaD and VirG (BSDV) that was encapsulated in chitosan nanoparticles as a vaccine candidate. The BSDV protein was expressed, purified, and loaded into chitosan nanoparticles using the ionic gelation method. Nanoparticle size, zeta potential, and protein release were characterized. Mice were immunized with free BSDV, BSDV with adjuvant, or BSDV encapsulated in chitosan nanoparticles, and immune responses (IgG and IgA) as well as survival after Shigella dysenteriae and Shiga toxin (Stx) challenge were evaluated. The purified BSDV protein had a final concentration of 16 mg/L. The chitosan nanoparticles showed an average size of 234.2 ± 23.9 nm with a zeta potential of 15.1 ± 0.9 mV. Protein release was gradual, with 50% released within 24 h and 72% by day 8. Immunization with BSDV encapsulated in chitosan nanoparticles induced significantly higher IgG and IgA titers compared to the other groups (p < 0.05) and provided 100% protection against 10LD50 of S. dysenteriae and 80% against 100LD50 of Stx. Our results indicate that chitosan-encapsulated BSDV induced protective immunity and is a promising candidate vaccine against the infections of Shigella dysenteriae.